Rossari Biotech Ltd · NSE:ROSSARI
Rossari Biotech — Q1 FY2021 Earnings Presentation
21 slides from Rossari Biotech's earnings presentation, Aug 21, 2020
Slide 1: Exchange filing cover letter
August 21, 2020 DCS-CRD Listing Compliance BSE Limited National Stock Exchange of India Ltd. First Floor, New Trade Wing Exchange Plaza, 5th Floor Rotunda Building, Plot No.C/1, ‘G’Block Phiroze Jeejeebhoy Towers Bandra- Kurla Complex Dalal Street, Fort Bandra East Mumbai 400 023 Mumbai 400 051 Fax
Slide 2: Rossari Biotech Limited Q1 FY21 Results Presentation
Rossari Biotech Limited Q1 FY21 Results Presentation August 21, 2020
Slide 3: Disclaimer
Disclaimer Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Ltd (Rossari) in the presentation (“forward- looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to
Slide 4: Q1 FY21 Results Overview
Q1 FY21 Results Overview
Slide 5: Q1 FY21 – Key Financial Highlights
Q1 FY21 – Key Financial Highlights Revenue from Operations EBITDA PAT (Rs. In cr) (Rs. In cr) (Rs. In cr) 23.7 15.5 127.8 22.3 14.2 109.5 Q1 FY20 Q1 FY21 Q1 FY20 Q1 FY21 Q1 FY20 Q1 FY21 Shift % (Y-o-Y) -14.4% Shift % (Y-o-Y) 6.4% Shift % (Y-o-Y) 9.4% Margins (%) 17.5% 21.7% Margins (%) 11.1% 14.2% 4
Slide 6: Management Message
Management Message Commenting on the performance for the quarter, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said “We are pleased to present our first financial results following our successful public listing in July 20
Slide 7: Key Developments
Key Developments Commissioned 1st phase of Greenfield manufacturing facility at Dahej • In July 2020, the Company successfully commissioned the first phase of its Greenfield manufacturing facility at Dahej, Gujarat • Rossari will be undertaking a phase-wise commissioning of the plant – expected to b
Slide 8: Key Developments
Key Developments Covid-19 Impact on Business operations and response: • The Company’s business operations in Q1 FY21 were impacted due to the unprecedented operating environment and prevailing macro-conditions due to the proliferation of the COVID-19 pandemic • As per the relaxations provided by the
Slide 9: Consolidated P&L Statement
Consolidated P&L Statement Particulars (Rs. crore) Q1 FY21 Q1 FY20 Y-o-Y Change (%) Revenues from Operations 109.5 127.8 -14.4% Total Expenditure 85.7 105.5 -18.7% • Raw Material expenses 63.8 80.6 -20.9% • Employee benefits expense 7.4 8.0 -8.1% • Other expenses 14.6 16.9 -13.3% EBITDA 23.7 22.3 6.
Slide 10: Q1 FY21 – Business-wise Details
Q1 FY21 – Business-wise Details Business-wise Revenue Break-up (Rs. Crore) HPPC TSC AHN 83.5 61.5 53.7 12.6 17.3 8.7 Q1 FY20 Q1 FY21 Revenue Shift HPPC TSC AHN (Y-o-Y) % 35.8% -67.8% -31.1% Key Highlights: • The Company witnessed strong momentum in the HPPC business, driven by improved demand and sa
Slide 11: Q1 FY21 - Financial and Operational Discussions (Y-o-Y)
Q1 FY21 - Financial and Operational Discussions (Y-o-Y) Net Revenues Revenues from operations stood at Rs. 109.5 crore from Rs. 127.8 crore • The Company remained agile and addressed available market opportunities in the HPPC business given its fungible manufacturing establishment • As the country m
Slide 12: Conference Call Details
Conference Call Details Q1 FY21 Earnings Conference Call Time • 05:00 p.m. IST on Monday, August 24, 2020 Primary dial-in number • + 91 22 6280 1145 / 7115 8046 India Local access Number • +91 70456 71221 (Available all over India) • Hong Kong: 800 964 448 International Toll Free Number • Singapore:
Slide 13: Company Overview
Company Overview
Slide 14: Company Overview
Company Overview Technocrat promoters with 45+ 2 120,000 2 42% 60% cumulative years of Manufacturing MTPA R&D Facilities: Revenue CAGR % PAT CAGR % experience in the locations: Production capacity Silvassa, Gujarat & IIT (FY18-20) (FY18-20) speciality chemicals industry Silvassa and Dahej, Mumbai, M
Slide 15: Customer Centric and Sustainability Focused R&D Capabilities
Customer Centric and Sustainability Focused R&D Capabilities Two R&D Formulations facilities: Silvassa and Rossari Rich experience Synthesis & across the Centre for Research Development Excellence - IIT business leading Mumbai to expertise in formulation and development Integrated Capabilities Techn
Slide 16: Expansion of Manufacturing Capacity
Expansion of Manufacturing Capacity Total Capacity Manufacturing Facility at Silvassa 2.1x (‘000 MTPA) Expansion of 132.5 capacity from Located on 8.6 acres of land 120,000 to 252,500 MTPA Fungible manufacturing capabilities for powders, 80 120 120 granules and liquids 60 Facility has a compre
Slide 17: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Founders & Promoters Independent Directors • B. Sc. (chemistry major) from K. J. Somaiya College of • Completed her basic education from Lawrence School Lovedale, University Science, University of Bombay & B. Sc. (technology) in Meher of Cambridge textile
Slide 18: Proven Track Record of Robust Financial Performance
Proven Track Record of Robust Financial Performance Revenue from Operations (INR cr) Operational leverage driving higher margins FY18 FY19 FY20 CAGR: 42% EBITDA (INR cr) EBITDA Margin (%) PAT (INR cr) PAT Margin (%) 299 17.5% 10.9% Total 516 600 14.3% 15.0% 8.5% 8.8% 29 AHN 52 57 214 TSC 269 262 55
Slide 19: Key Strengths
Key Strengths Diversified product portfolio Providing intelligent and sustainable chemical solutions for customers across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Wide sales and distribution network Chemicals, Performance Chemicals, the Animal Health and Nutrition an
Slide 20: Strategic Growth Levers
Strategic Growth Levers Augmenting product portfolio with enhanced emphasis on green solutions Increase wallet share across existing customer base while also tapping new customer segments Identifying and developing new niches in product offerings by leveraging R&D capabilities Capitalize on cros
Slide 21: About Us
About Us Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), For further information, please contact: is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Manasi Nisal Headquartered at Mumbai, India, the Company operates 2